European Commission approves AbbVie’s RINVOQ® for treatment of Giant Cell Arteritis
1.RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved…
AbbVie acquires Nimble Therapeutics to advance autoimmune and psoriasis treatments
December 2024- AbbVie and Nimble Therapeutics announced a definitive agreement under which…
AbbVie Awards Scholarships to 45 Students with Chronic Diseases
NORTH CHICAGO, Ill- AbbVie recently announced the 2024-2025 recipients of the AbbVie…
EU Approves TEPKINLY® for Relapsed/Refractory Follicular Lymphoma
NORTH CHICAGO, Ill.- AbbVie recently announced that the European Commission (EC) has…
AbbVie Completes Acquisition of Cerevel Therapeutics
North Chicago- August 2024- AbbVie announced that it has completed its acquisition…
AbbVie Launches Contest to Empower People Living with Migraine in their Careers
June 20204- AbbVie launched the AbbVie Migraine Career Catalyst Award, a first-of-its-kind…
AbbVie Completes Acquisition of Landos Biopharma
North Chicago- May 2024- AbbVie announced that it has completed its acquisition…
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
Irvine- April, 2024- Allergan Aesthetics, an AbbVie company announced the launch of…
AbbVie to Acquire Landos Biopharma
NewYork- April 2024- AbbVie and Landos Biopharma announced a definitive agreement under…
Game-Changing Cancer Treatment: AbbVie and Umoja Biopharma Partner Up
North Chicago, USA- Pharmaceutical giant AbbVie and early clinical-stage biotech company Umoja…